




Figures 1A – 1C




Figure 1D




Figure 2A – Figure 2B




Figure 3A – Figure 3B




Figure 4

Identity Matrix Results		PGX9256_1A2_L	PGX9290_EBV114_L
VL	232_L	57.5	67.8
	214_L	57.5	76.6
No CDR	232_L	67.8	64.4
	214_L	67.8	85.6
FR1 only	232_L	50	45.5
	214_L	50	90.9
FR4 only	232_L	90	80
	214_L	100	90

Figure 5





Figure 6









Figure 8A – 8D




Figure 9A – 9F




Figure 10A – 10E




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15A – 15B

	Group 1				Control
	EBOMAb-10	EBOMAb-10-2	EBOMAb-10-3	EBOMAb-10-4	
Antibodies	IgG (Control)	ScFv-Fc-	IgG Partial Graft	ScFv-Fc Partial Graft	KZ52-IgG
IC50 (µg/ml)	0.062	0.026	0.019	0.029	
IC90 (µg/ml)	0.2	0.41	0.053	0.073	0.45
% Max Neutralization	99	99	99	99	1.83
IC90 (% of IgG Control)	n.a	184%	24%	33%	92
	Group 2				
	EBOMAb-14	EBOMAb-14-2	EBOMAb-14-3	EBOMAb-14-4	
Antibodies	IgG	ScFv-Fc	IgG Partial Graft	IgG Partial Graft	
IC50 (µg/ml)	0.26	0.37	0.11	0.37	
IC90 (µg/ml)	0.84	1.07	0.28	0.84	
% Max Neutralization	99	91	99	92	
IC90 (% of IgG Control)	n.a	127%	33%	65%	

Figure 16




Figure 17A – 17F





Fig. 18A-18B

A



B

Normalized Serum ZIKV Antigen Binding





Fig. 19A-19B







Fig. 21A-21B



B

Normalized Serum ZIKV Antigen Binding




Fig. 22A-22B




Fig. 23




Fig. 24




Fig. 25A – 25B




Fig. 26A – 26D




Fig. 27




Fig. 28




Fig. 29A – 29D




Fig. 30




Fig. 31A – 31B






Fig. 32A – 32C


Zika Antigen Binding




DENV1 Antigen Binding



DENV2 Antigen Binding



DENV3 Antigen Binding



DENV4 Antigen Binding






Fig. 33

A In vitro Expression of Zika & Dengue scFv-Fc



B



C




Fig. 34A – 34C




A**Peak expression of Zika & Dengue scFv-Fcs****B****Zika Antigen Binding****C****Dengue Antigen Binding**

Fig. 35A – 35C